Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Immatics Yönetim

Yönetim kriter kontrolleri 3/4

Immatics' CEO'su Harpreet Singh, Jul2019 tarihinde atandı, in görev süresi 5.25 yıldır. in toplam yıllık tazminatı € 6.38M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.7% maaş ve 92.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.24% ine doğrudan sahiptir ve bu hisseler $ 14.57M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 3.4 yıldır.

Anahtar bilgiler

Harpreet Singh

İcra Kurulu Başkanı

€6.4m

Toplam tazminat

CEO maaş yüzdesi	7.7%
CEO görev süresi	5.3yrs
CEO sahipliği	1.2%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18

Immatics reports Q3 results

Dec 02

Immatics (IMTX) Investor Presentation - Slideshow

Nov 13

CEO Tazminat Analizi

Harpreet Singh'un ücretlendirmesi Immatics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€74m
Mar 31 2024	n/a	n/a	-€80m
Dec 31 2023	€6m	€488k	-€97m
Sep 30 2023	n/a	n/a	-€84m
Jun 30 2023	n/a	n/a	-€79m
Mar 31 2023	n/a	n/a	-€68m
Dec 31 2022	€7m	€522k	€38m

Tazminat ve Piyasa: Harpreet 'nin toplam tazminatı ($USD 7.06M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.23M ).

Tazminat ve Kazançlar: Harpreet 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Harpreet Singh (49 yo)

5.3yrs

Görev süresi

€6,378,000

Tazminat

Dr. Harpreet Singh, Ph D., has been Non-Executive Director of Immatics N.V. since July 1, 2021 and served as its Supervisory Director since 2021 until July 1, 2021. Dr. Singh serves as Chief Executive Offi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harpreet Singh	CEO, MD	5.3yrs	€6.38m	1.24% € 13.9m
Toni Weinschenk	Co-Founder & Chief Innovation Officer	24.8yrs	Veri yok	0.31% € 3.5m
Arnd Christ	Chief Financial Officer	4yrs	Veri yok	0.16% € 1.8m
Steffen Walter	Chief Operations Officer	1.6yrs	Veri yok	0.27% € 3.0m
Edward Sturchio	General Counsel & Secretary	4.3yrs	Veri yok	0.10% € 1.2m
Carsten Reinhardt	Chief Development Officer	5yrs	Veri yok	0.45% € 5.0m
Cedrik Britten	Chief Medical Officer	4.3yrs	Veri yok	0.22% € 2.5m
Jordan Silverstein	Head of Strategy	no data	Veri yok	0.19% € 2.1m
Hans-Georg Rammensee	Co-Founder & Member of the Scientific Advisory Board	24.8yrs	Veri yok	Veri yok
Ephraim Hofsäß	Vice President of SEC Reporting & Accounting	less than a year	Veri yok	Veri yok
Emmanuelle Schuler	VP of Administration & Operations and US Site Head	no data	Veri yok	Veri yok
Tamara Louw	VP of Human Resources & US Site Head	2.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: IMTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harpreet Singh	CEO, MD	3.3yrs	€6.38m	1.24% € 13.9m
Hans-Georg Rammensee	Co-Founder & Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Atieh	Independent Non-Executive Director	3.3yrs	€263.00k	0.054% € 600.7k
Peter Chambré	Non-Executive Chairman	3.3yrs	€283.00k	0.36% € 4.1m
Heather Mason	Independent Vice Chair of the Board of Directors	3.3yrs	€246.00k	0.054% € 600.7k
Hidde L. Ploegh	Member of Scientific Advisory Board	4.3yrs	Veri yok	Veri yok
Patrick Hwu	Co-Chair of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Paul Rutherford Carter	Independent Non-Executive Director	3.3yrs	€259.00k	0.054% € 600.7k
Cassian Yee	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gwendolyn Binder	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Crystal Mackall	Co-Chair of the Scientific Advisory Board	4.1yrs	Veri yok	Veri yok
Roland Kontermann	Member of Scientific Advisory Board	4.3yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Immatics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V., Annual General Meeting, Jun 20, 2023

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics N.V. Announces Executive Changes

Recent updates

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.9% to US$17.50

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 10%

New major risk - Revenue and earnings growth

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Price target increased by 8.2% to US$19.83

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 42%

Investor sentiment improves as stock rises 22%

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 76%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Immatics launches $110M stock offering

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Price target decreased to US$20.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Price target decreased to US$22.80

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Consensus forecasts updated

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Consensus forecasts updated

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.38 loss per share (vs €18.08 loss in 2Q 2020)

Supervisory Director Christof Hettich has left the company

Supervisory Director Christof Hettich has left the company

Consensus forecasts updated

First quarter 2021 earnings released: €0.34 loss per share (vs €7.14 loss in 1Q 2020)

Immatics Presents Preclinical Proof-Of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Full year 2020 earnings released: €4.77 loss per share (vs €0.95 loss in FY 2019)

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

New 90-day high: US$11.56

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?